Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Episodes
125 total · newest first
Press play on any episode and the show keeps running from there.
An $11.6B yes, $11.7B delay, drop the AIC with GLP, and a billion bio-bucksFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizer + BiohavenRegulatorsLillyBridgeBio + BMSAbout the ShowLife Science Today is your source for…
Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal dealFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesZymeworksPhathomCatalystCenExelIntercept + AdvanzAbout the ShowLife Science To…
Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle loomsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesMerckSanofiJ&JThermoFisherNovo NordiskEli LillyAbout the ShowLife Science T…
Drops for reading, a $220M raise, and an acquisition straight out of the moviesFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesOrasisReifyBlackrock + MindXAbout the ShowLife Science Today is your source for stories, insig…
The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesFDAAntares + HalozymeGSK + SierraAnsa BiotechnologiesAbout the ShowLife S…
Viral therapies, rare disease approvals, and lab space premiumsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizer + ReViralNovartisCharles River + Explora LabsAbout the ShowLife Science Today is your source for storie…
Big compensation, mild mergers, a Kite in an updraft, and tightening the biotech beltFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGinkgoEagle + AcaciaGileadTaysha/Orchard/SilverbackAbout the ShowLife Science Today is y…
$2 billion in capital raises mostly by companies that start with the letter A. Find out more athttps://LifeScienceTodayPodcast.comStory References2seventy BioAscendisApellisArgenxAbout the ShowLife Science Today is your source for stories, …
Case closed on patents, Alzheimer’s data, generic approvals, and expanded approvals. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlexion + ChugaiBiogenViatrisAbbVieAbout the ShowLife Science Today is your source for s…
Technology for inclusion, layoffs, oncology approvals, and $200M for a tech platform. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesGileadAstraZeneca + Merck + MyriadDNAnexus About the ShowLife Science Today is your sou…
Who owns CRISPR, a collaboration, the classics, and more money for biotech.Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesSanofi + AdageneAbbVie + SyndesiAtlasAbout the ShowLife Science Today is your source for stories, …
CRISPR works, the opioid epidemic makes amends (sort of), and the SPAC that wasn’tFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIntelliaPurdue PharmaAmicus SPACAbout the ShowLife Science Today is your source for stories…
The PD1 that lost, biopharma earns FDA approval, and the Biotech market is cool not dead Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesEli Lilly + Innovent BiologicsAgiosTC BiopharmBlue Water VaccinesMeihua About the Sh…
Dragons over unicorns, to CRISPR and beyond, spin-out-and-sell, and expanded approvals. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesArcellxIntellia + RewriteNavitor + JanssenViiV About the ShowLife Science Today is yo…
Bispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetimeFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGenentechImmunocoreBiogenEli LillyTenSixteenAbout the ShowLife Science Tod…
Psychedelic SPACs, eczema frenzy, bio-outs without the biobucks, back on track, and the mega-deal that wasn’t Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesEleusisAbbvie/Pfizer/LeoUCB + ZogenixKuraGSK - UnileverAbout th…
Oncology partners, Parkinson’s partners, expanded European Commission, expanded FDA, and bacterial vaccinesFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesScorpion & AstraZeneca ABL & SanofiVertexCochlearVaxcyteAb…
Devices with tech enablement, nano particles, Chinese approvals, and a massive series B for biotechnologyFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesStryker + VoceraMerck KGaA + ExeleadBeiGeneEikonAbout the ShowLife S…
We’ve got a new name, gene therapy buyout, a lion of an approval, and an in-escapable spotlight. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesNovartis + GyroscopeLeoBiogenBiogen 2About the ShowLife Science Today is you…
Acquiring the acquired, EHR acquisition, first approvals, and a new fund for the new yearFind out more athttps://thenichepod.comStory ReferencesCSL + ViforOracle + CernerCalliditasOmegaAbout the ShowThe Niche Podcast brings you interviews w…
Antitrust AI, development AI, expanded approval, mega seeds, and biosimilar SPACsFind out more athttps://thenichepod.comStory ReferencesMicrosoft + NuanceRoche + RecursionHeron1EAlvotech Music by Luke GoodsonAbout the ShowThe Niche Podcast …
Double acquisitions in Switzerland, FDA holds and what that means, CMV therapy, rare + oncology continues, BioCryst draws millions, and deer. Find out more athttps://thenichepod.comStory ReferencesVifor + Sanifit + InositecKuraDifferential …
Top dollar lab notes, lab consolidation, RNA sells, and two new approval areas Find out more athttps://thenichepod.comStory ReferencesBenchlingLabcorpNovo NordiskBioMarinBioMarin 2AppliedVRAppliedVR 2Music by Luke Goodsonhttps://www.soundcl…
A giant breaks in two, acquisitions in women’s health, Medicare cost, rare approvals, more CRISPR, and a legacyFind out more athttps://thenichepod.comStory ReferencesJohnson & JohnsonOrganonMedicarePharmaEssentiaArbor BiotechnologiesGle…
